78 related articles for article (PubMed ID: 18381964)
41. Structure activity relationships of quinoline-containing c-Met inhibitors.
Kung PP; Funk L; Meng J; Alton G; Padrique E; Mroczkowski B
Eur J Med Chem; 2008 Jun; 43(6):1321-9. PubMed ID: 17964000
[TBL] [Abstract][Full Text] [Related]
42. Copper regulated synthesis, secretion and degradation of ceruloplasmin in a mouse immortalized hepatocytic cell line.
Pisu P; Bellovino D; Gaetani S
Cell Mol Biol (Noisy-le-grand); 2005 Dec; Suppl 51():OL859-67. PubMed ID: 16405854
[TBL] [Abstract][Full Text] [Related]
43. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer.
Hanahan D; Wagner EF; Palmiter RD
Genes Dev; 2007 Sep; 21(18):2258-70. PubMed ID: 17875663
[TBL] [Abstract][Full Text] [Related]
44. Apoptosis and chemoresistance in transgenic cancer models.
Schmitt CA; Lowe SW
J Mol Med (Berl); 2002 Mar; 80(3):137-46. PubMed ID: 11894140
[TBL] [Abstract][Full Text] [Related]
45. Correction for Smolen et al., Amplification of
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2410435121. PubMed ID: 38870064
[No Abstract] [Full Text] [Related]
46. Lymphoma cutis with spontaneous regression.
CHATTERJEE PK; MUKHERJEE AM
J Indian Med Assoc; 1957 Dec; 29(12):477-81. PubMed ID: 13502567
[No Abstract] [Full Text] [Related]
47. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.
McDonald JT; Kritharis A; Beheshti A; Pilichowska M; Burgess K; Ricks-Santi L; McNiel E; London CA; Ravi D; Evens AM
Oncotarget; 2018 Apr; 9(32):22693-22702. PubMed ID: 29854308
[TBL] [Abstract][Full Text] [Related]
48. The role of HGF/c-MET signaling pathway in lymphoma.
Lam BQ; Dai L; Qin Z
J Hematol Oncol; 2016 Dec; 9(1):135. PubMed ID: 27923392
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
[TBL] [Abstract][Full Text] [Related]
50. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
Dai Y; Siemann DW
BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
[TBL] [Abstract][Full Text] [Related]
51. Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.
Guo T; Zhu Y; Gan CS; Lee SS; Zhu J; Wang H; Li X; Christensen J; Huang S; Kon OL; Sze SK
Mol Cell Proteomics; 2010 Dec; 9(12):2629-41. PubMed ID: 20713453
[TBL] [Abstract][Full Text] [Related]
52. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
[TBL] [Abstract][Full Text] [Related]
53. Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors.
Cao X; Littlejohn J; Rodarte C; Zhang L; Martino B; Rascoe P; Hamid K; Jupiter D; Smythe WR
Am J Pathol; 2009 Nov; 175(5):2207-16. PubMed ID: 19834061
[TBL] [Abstract][Full Text] [Related]
54. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
55. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
56. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
57. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation.
Lal B; Xia S; Abounader R; Laterra J
Clin Cancer Res; 2005 Jun; 11(12):4479-86. PubMed ID: 15958633
[TBL] [Abstract][Full Text] [Related]
58. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
59. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
